Entering text into the input field will update the search result below

MediciNova preparing late-stage study of ibudilast in subtype of MS

Apr. 02, 2019 7:14 AM ETMediciNova, Inc. (MNOV) StockBy: Douglas W. House, SA News Editor
  • MediciNova (NASDAQ:MNOV) is finalizing the protocol of a new Phase 3 program evaluating MN-166 (ibudilast) in patients with secondary progressive multiple sclerosis (MS) without relapse, a subgroup of MS sufferers with no currently available medications to treat their condition.
  • The company recently conducted a further analysis of the Phase 2b SPRINT-MS study of MN-166 in patients with progressive MS that showed patients with secondary progressive MS with relapse experienced 46% less risk of disease progression compared to placebo.

Recommended For You

More Trending News

About MNOV Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
MNOV--
MediciNova, Inc.